Europe Faces Critical Barriers to Cancer Drug Combinations, Study Finds

A new policy review identifies major obstacles preventing European patients from accessing combination cancer therapies—including fragmented pricing rules and slow regulatory pathways. The findings suggest policymakers must coordinate across countries to unlock these treatments, which could improve outcomes for millions while streamlining market entry for pharmaceutical companies.

Originaltitel: Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe